199
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders

, , , , , , , , & show all
Pages 241-246 | Received 03 Aug 2021, Accepted 04 Nov 2021, Published online: 16 Nov 2021

References

  • European Centre for Disease Prevention and Control [Internet]. Solna (Sweden): ECDPC; 2021 [cited 2021 June 13]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
  • Carbone M, Lednicky J, Xiao S-Y, et al. Coronavirus 2019 infectious disease epidemic: where we are, what can be done and hope for. J Thorac Oncol. 2021;16(4):546–571.
  • Raoult D. How useful is serology for COVID-19? Int J Infect Dis. 2021;102:170–171.
  • Busch MP, Stone M. Serosurveillance for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence using global blood donor populations. Clin Infect Dis. 2021;72(2):254–256.
  • Sughayer MA, Mansour A, Nuirat AA, et al. Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: the evolution of a pandemic. Int J Infect Dis. 2021;107:116–120.
  • Byambasuren O, Dobler CC, Bell K, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review. PLoS One. 2021;16(4):e0248946.
  • Zhenyu H, Ren L, Yang J, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. The Lancet. 2021;397:P1075–P1084.
  • Vos ERA, Hartog GD, Schepp RM, et al. Nationwide seroprevalence of Sars-CoV-2 and identification of risk factors in the general population of The Netherlands during the first epidemic wave. BMJ Journals. 2020;75:P489–P495.
  • Liu A, Li Y, Wan Z, et al. Seropositive prevalence of antibodies against SARS-CoV-2 in wuhan, China. JAMA Netw Open. 2020;3(10):e2025717.
  • Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to Sars-CoV-2 in 10 sites in the United States, march 23-May 12, 2020. JAMA Intern Med. 2020;180(12):1576–1586.
  • Winter AK, Martinez ME, Cutts FT, et al. Benefits and challenges in using seroprevalence data to inform models for measles and rubella elimination. J Infect Dis. 2018;218(3):355–364.
  • Triggle CR, Bansal D, Ding H, et al. A comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and covid-19 as a basis for controlling the pandemic. Front Immunol. 2021;12:P338.
  • Gouvea dos Santos W. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines. Biomed Pharmacother. 2021;136:111215–111272.
  • Di Stefano M, Sarno M, Faleo G, et al. Low prevalence of antibodies to SARS-CoV-2 and undetectable viral load in seropositive blood donors from South-Eastern Italy. Acta Haematol. 2021;144(5):580–584.
  • Fiore JR, Centra M, Carlo AD, et al. Results from a survey in healthy blood donors in South-Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. J Med Virol. 2021;93(3):1739–1742.
  • Somekh I, Sharabi A, Dory Y, et al. Intrafamilial spread and altered symptomatology of SARS-CoV-2 during predominant circulation of lineage B.1.1.7 variant in Israel. Pediatr Infect Dis J. 2021;40(8):e310–e311.
  • Valenti L, Pelusi S, Cherubini A, et al. Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors. Transfusion. 2021. DOI:https://doi.org/10.1111/trf.16693
  • Muller CP. Do asymptomatic carriers of SARS-COV-2 transmit the virus? The Lancet Regional Health Europe. 2021;4:P1–P6.
  • Wilmes P, Zimmer J, Schulz J, et al. SARS-CoV-2 transmission risk from asymptomatic carriers: results from a mass screening programme in Luxembourg. Lancet Regional Health Europe. 2021;4:100056–100059.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.